Impact of early tumor shrinkage on clinical outcome in KRAS wild-type colorectal liver-limited metastases treated with cetuximab plus chemotherapy: Lessons from a randomized controlled trial.

Authors

Le-chi Ye

Department of General Surgery, Zhongshan Hospital, Fudan, Shanghai, China

Le-chi Ye , Yunshi Zhong , Tianshu Liu , Ye Wei , Li Ren , Dexiang Zhu , Xinyu Qin , Jia Fan , Jingwen Chen , Wenju Chang , Qi Lin , Jianmin Xu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Gastrointestinal Cancers Symposium

bookmark_border

Preoperative chemotherapy prior to primary tumor resection for asymptomatic synchronous unresectable colorectal liver-limited metastases: A multicenter randomized controlled trial.

First Author: Qi Lin

insert_chart_outlined

Poster

2018 Gastrointestinal Cancers Symposium

bookmark_border

Keynote-177: Phase 3, open-label, randomized study of first-line pembrolizumab (Pembro) versus investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC).

First Author: Luis A. Diaz Jr.

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

Phase 3, open-label, randomized study of first-line pembrolizumab (pembro) vs investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC): KEYNOTE-177.

First Author: Luis A. Diaz Jr.

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

KEYNOTE-177: first-line, open-label, randomized, phase 3 study of pembrolizumab versus investigator-choice chemotherapy for mismatch repair–deficient or microsatellite instability–high metastatic colorectal carcinoma.

First Author: Luis A. Diaz Jr.